Mylan NV (MYL)

neg -0.59
Today's Range: 37.65 - 38.77 | MYL Avg Daily Volume: 7,175,900
Last Update: 10/26/16 - 3:59 PM EDT
Volume: 7,047,124
YTD Performance: -28.46%
Open: $38.48
Previous Close: $38.68
52 Week Range: $37.59 - $67.34
Oustanding Shares: 534,911,497
Market Cap: 20,091,275,827
6-Month Chart
TheStreet Ratings Grade for MYL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 3 3 5
Moderate Buy 0 0 0 0
Hold 5 6 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.91 2.33 2.25 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.54%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 23.48
Price Earnings Comparisons:
MYL Sector Avg. S&P 500
23.48 22.00 29.60
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-18.19% -5.57% 0.65%
Revenue 22.10 0.40 0.11
Net Income -9.20 0.30 0.10
EPS -27.00 0.20 0.05
Earnings for MYL:
Revenue 9.43B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $1.51 $1.40 $4.81 $5.60
Number of Analysts 8 7 7 9
High Estimate $1.57 $1.48 $4.90 $6.00
Low Estimate $1.40 $1.31 $4.74 $5.32
Prior Year $1.43 $1.22 $4.30 $4.81
Growth Rate (Year over Year) 5.86% 14.52% 11.83% 16.53%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
The likely continuation of a split government should help the sector recover from its recent beat-down.
With Clinton apparently headed for victory, worries about her being a threat to health-care stocks have peaked.
Thanks to everyone who contributed to the conversation on the Daily Diary today. It was quite a lively bunch.
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
Mylan rose after settling with the U.S. Department of Justice for $465 million over the way it overcharged Medicaid for the EpiPen.
Brexit concerns pummel the pound while Alphabet gets set to unveil several new devices.
Sep 30, 2016 | 7:13 AM EDT
Shares of MYL now seen reaching $45, according to Leerink Partners. Estimates also cut, as an authorized generic EpiPen product will li...
It appears Twitter will need more than takeover chatter to stay aloft, Oppenheimer analysts say.
Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.
The bear is in control.

Columnist Conversations

Raytheon is building on Tuesday's impressive breakout.  The defense name is up over 1.25% ahead of tonigh...
Merck had a nice earnings beat on Tuesday which was accompanied by an earlier than expected FDA approval on Ke...
For years Apple was accused of under promise, over deliver --- UPOD as Jim Cramer likes to call it.  Whil...
Market down across the board, as less than optimistic outlook from Apple (AAPL) dampens investor enthusiasm in...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.